Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM), the Marketing Authorisation Application for Diclectin® is now considered approvable. Alliance awaits issue of the formal Marketing Authorisation from the MHRA in the coming weeks, with UK launch anticipated to be in the Autumn of this year.

Diclectin, a prescription treatment for nausea and vomiting of pregnancy, was in-licensed from Duchesnay Inc. of Canada (“Duchesnay”) for the UK in 2015 and for a further nine European territories in 2016*.

Diclectin has a well-established efficacy and safety profile and is regarded as the standard of care for nausea and vomiting of pregnancy in Canada, where it has been used for over 40 years and has been prescribed for more than 30 million women. In 2013, Diclectin (“Diclegis”) was approved in the United States with the highest possible safety rating for drugs used during pregnancy, FDA Category A, and has since been approved in Israel, South Korea and Singapore.

Following the approval of Diclectin in the UK, Alliance then expects to commence the filing of the necessary applications for regulatory approvals for further European territories in advance of launches later in 2019.

Commenting on the news, Peter Butterfield, Alliance Pharma’s Chief Executive Officer, said:
“We are delighted by this news and look forward to launching Diclectin later this year. There are currently no licensed treatments for nausea and vomiting of pregnancy in the UK, highlighting a clear unmet need for patients and clinicians. For Alliance, Diclectin represents a sizeable mid-term opportunity and also allows us to further leverage our European footprint.”

Éric Gervais, Duchesnay’s Executive Vice-President, added:
”Nausea and vomiting of pregnancy is a common medical condition that can affect up to 80% of all pregnant women. It can be debilitating and can worsen if left untreated. We continue to support Alliance in their efforts to provide a licensed treatment, which has a proven safety and efficacy profile, for women in the UK suffering from morning sickness.”

*Austria, Belgium, France, Germany, Italy, Luxembourg, Netherlands, Republic of Ireland, Switzerland,

Notes to editors:

Alliance Pharma plc is an international specialty pharmaceutical company.
Headquartered in Chippenham, UK, Alliance commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

Duchesnay Inc. is a North American specialty pharmaceutical company.
Headquartered in Blainville, Canada, Duchesnay is a specialty pharmaceutical company with a longstanding commitment to women’s health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that have established safety and efficacy profiles for use during pregnancy and breastfeeding. With offices in Canada and the United States, Duchesnay also commercializes a broad portfolio of products to offer proven therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives.

Latest news

GT Medical Technologies Names Per Langoe As CEO
February 20, 2024

Full release here: GT Medical Technologies, Inc. Names Per Langoe As CEO

MVM invests in icotec
January 24, 2024

ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PR Newswire/ — icotec ag, the leading company in the field of innovative spinal […]

MVM invests in Gynesonics
November 1, 2023

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Gynesonics® Inc., a women’s healthcare company focused on the development of […]

SkyCell Featured in TechCrunch
October 31, 2023

Full release here: SkyCell raises $57M at a $600M valuation to build smart containers for pharmaceutical transport | TechCrunch

MVM invests in BioProtect
September 27, 2023

TZUR IGAL, Israel, Sept. 27, 2023 /PRNewswire/ — BioProtect Ltd, a private Med Tech company focused on providing innovative, biodegradable spacing solutions, announced today the […]

VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023

SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]

MVM invests in CurvaFix
July 14, 2023

BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023

ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023

TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]